Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis
- 10 January 2023
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 21 (3) , 489-499
Abstract
Objective This study evaluated the cost effectiveness of denosumab versus alendronate for secondary prevention of osteoporotic fractures among post-menopausal women in China. Methods A validated individual-level simulation model of osteoporotic fractures in the Chinese setting was adapted. Allowing both treatment discontinuation and waning effects, the analysis aimed to evaluate the incremental cost-effectiveness ratio of denosumab compared to alendronate by simulating a cohort of previously fractured individuals over the residual lifetime from the healthcare system perspective. Hip, vertebral, and wrist/humeral fractures were tracked along with the associated medical costs and quality-adjusted life-years. Age-related health state utility values, health state utility values of fractures, costs, fracture incidence, and mortality risks for Chinese were used whenever available. Comparative effectiveness data were obtained from a published network meta-analysis. One-way and probabilistic sensitivity analyses were conducted. Results In the base case, denosumab was dominated by alendronate with incremental costs of CN¥2743 (US$425) and incremental health outcomes of − 0.20 quality-adjusted life-years at its current price in mainland China. It remained dominated in all one-way sensitivity analysis robustness checks. However, denosumab was cost effective if both drugs did not carry any waning effects. In the probabilistic sensitivity analysis, denosumab remained dominated in all replications. Conclusions Denosumab is not cost effective for preventing secondary fractures among overall postmenopausal women in China. It is advisable to identify alternative denosumab regimens for high-risk subgroups among previously fractured postmenopausal women.Keywords
Funding Information
- National Natural Science Foundation of China (72004242)
This publication has 42 references indexed in Scilit:
- Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysisOsteoporosis International, 2012
- Ethnic difference of clinical vertebral fracture riskOsteoporosis International, 2011
- Updated fracture incidence rates for the US version of FRAX®Osteoporosis International, 2009
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and WomenJAMA, 2009
- Ten-Year Risk of Osteoporotic Fractures in Postmenopausal Chinese Women According to Clinical Risk Factors and BMD T-Scores: A Prospective StudyJournal of Bone and Mineral Research, 2007
- Risk of mortality following hip fracture in JapanJournal of Orthopaedic Science, 2007
- Risk of Subsequent Fracture After Low-Trauma Fracture in Men and WomenJAMA, 2007
- Persistence with weekly alendronate therapy among postmenopausal womenOsteoporosis International, 2006
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Osteoporosis: Review of the Evidence for Prevention, Diagnosis and Treatment and Cost-Effective AnalysisOsteoporosis International, 1998